References

PRINT AS PDF
  1. Australasian Sexual Health Alliance (ASHA). Australian STI management guidelines for use in primary care [internet]. Taking a sexual history and contact Updated December 2018. Available at: http:// www.sti.guidelines.org.au/resources/how-to-take-a-sexual-history#how-to-take-a-sexual-history (last accessed 3 September 2019).
  2. Grant RM, Sevelius JM, Guanira JV, Aguilar JV, Chariyalertsak S, Deutsch Transgender women in clinical trials of pre-exposure prophylaxis.J Acquir Immune Defic Syndr 2016;72 Suppl 3:S226-9. 
  3. Grant RM, Lama JR, Anderson PL, et al; iPrEx Study Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med 2010;363:2587-99. 
  4. Mehrotra ML, Westreich D, McMahan VM, et Baseline characteristics explain differences in effectiveness of randomization to daily oral TDF/FTC PrEP between transgender women and cisgender men who have sex with men in the iPrEx Trial. J Acquir Immune Defic Syndr 2019; 81:e94-8 
  5. Centers for Disease Control and Prevention (CDC). Integrated prevention services for HIV infection, viral hepatitis, sexually transmitted diseases, and tuberculosis for persons who use drugs illicitly: summary guidance from CDC and the S. Department of Health and Human Services.MMWR Recomm Rep 2012;61(RR-5):1–40.
  6. International Network of People who Use Drugs (INPUD). Position paper: pre-exposure prophylaxis (PrEP) for people who inject April 2015. Available at: www.inpud.net/INPUD_PositionPaper_Pre- exposure_prophylaxis_PrEP_April15.pdf (last accessed 3 September 2019). 
  7. Wodak A, Maher The effectiveness of harm reduction in preventing HIV among injecting drug users. NSW Public Health Bulletin 2010;21(3–4):69-73. 
  8. Kwon JA, Iversen J, Law M, Dolan K, Wand H, Maher Estimating the number of people who inject drugs and syringe coverage in Australia, 2005-2016. Drug Alcohol Depend 2019;197:108-14. 
  9. Bazzi AR, Drainoni ML, Biancarelli DL, et Systematic review of HIV treatment adherence research among people who inject drugs in the United States and Canada: evidence to inform pre-exposure prophylaxis (PrEP) adherence interventions. BMC Public Health 2019;19:31. 
  10. Biello KB, Bazzi AR, Mimiaga MJ, et Perspectives on HIV pre-exposure prophylaxis (PrEP) utilization and related intervention needs among people who inject drugs. Harm Reduct J 2018;15:55.